Cellular and molecular mechanisms of human choroidal and retinal vascularisation

人类脉络膜和视网膜血管化的细胞和分子机制

• 批准号: nhmrc : 464859
• 负责人: Prof Tailoi Chan-Ling
• 金额: $ 19.22万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/cellular-molecular-mechanisms-retinal-vascularisation/101310
• 关键词: Cellular; molecular; mechanisms; human; choroidal

The abnormal growth of new blood vessels is a major cause of blindness in people of all ages. In premature infants, changes in retinal blood vessels results in Retinopathy of Prematurity (ROP) the leading cause of infant blindness in the world. In older adults with age-related macular degeneration (ARMD), vessels in the choroid can grow into and under the retina where they can cause catastrophic loss of vision. This association of abnormal vessel growth with the most common causes of blindness has motivated the search for a better understanding of how blood vessel growth in the eye is controlled in healthy tissues and how these controls fail in disease. Our proposal addresses this issue directly. Recent work shows that this neovascularization is not only a response to a rise in the local concentration of molecules that induce such angiogenesis, but also requires a fall in the levels of endogenous molecules that inhibit angiogenesis. Our study will investigate the expression of newly identified angiogenic growth factors (VEGFs) and their receptors as well as angiogenic inhibitors (VEGI and PEDF) in the developing and adult human retina and choroid. We will examine the mechanisms by which the human choroid is formed. Our preliminary results suggests the novel insight that vasculogenesis (the formation of blood vessels via transformation of vascular precursor cells) plays a major role the formation of both the human retina and choroid. Further, these exciting results suggest involvement of novel growth stimulators and inhibitors previously not known to play a role in these processes. Our studies will lead to new insights regarding the vascular growth factors and inhibitors that drive this process, thus leading to a rational basis for new therapeutic targets for the treatment of ARMD. The rapid aging of the Australian population and the consequent predicted doubling of ARMD incidence in the next 20 years demonstrates the urgency of our studies.

新血管的异常生长是所有年龄段的人失明的主要原因。在早产儿中，视网膜血管的变化导致早产儿视网膜病变（ROP），这是世界上婴儿失明的主要原因。在患有年龄相关性黄斑变性（ARMD）的老年人中，脉络膜中的血管可以生长到视网膜内和视网膜下，在那里它们可以导致灾难性的视力丧失。异常血管生长与最常见的失明原因之间的这种关联促使人们更好地了解眼睛中的血管生长如何在健康组织中受到控制，以及这些控制如何在疾病中失败。我们的提案直接涉及这一问题。最近的工作表明，这种新血管形成不仅是对诱导这种血管生成的分子的局部浓度升高的响应，而且还需要抑制血管生成的内源性分子水平的下降。我们的研究将探讨新发现的血管生成生长因子（VEGF）及其受体以及血管生成抑制剂（VEGI和PEDF）在发育和成人视网膜和脉络膜中的表达。我们将研究人类脉络膜形成的机制。我们的初步结果表明，新的见解，血管生成（血管前体细胞的转化形成血管）起着重要作用的形成人类视网膜和脉络膜。此外，这些令人兴奋的结果表明，参与新的生长刺激剂和抑制剂以前不知道在这些过程中发挥作用。我们的研究将导致关于驱动这一过程的血管生长因子和抑制剂的新见解，从而为治疗ARMD的新治疗靶点提供合理的基础。澳大利亚人口的快速老龄化和随之而来的ARMD发病率在未来20年内预计将翻一番，这表明了我们研究的紧迫性。